Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke

Martynov, M. Yu.; Бойко, А. Н.; Камчатнов, П Р; Kabanov, A. A.; Yasamanova, A N; Ia, Shchukin; Kolesnikova, T. I.; Chubykin, V. I.; Glukhareva, A. P.; Gusev, E I

doi:10.1007/s11055-013-9797-x

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reference group included more patients with unsatisfactory recovery, i.e., with total points scores of ≤60 (OR 3.48, 95% CI 1.37–8.95, p = 0.013). In addition, on the mRS scale, patients from the research group obtained better results: 54 did not have significant symptoms and were able to perform everyday duties, whereas such an outcome was obtained by 17 people from the control group (OR 4.01, 95% CI 1.73–9.37, p = 0.0006) [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

Application of Citicoline in Neurological Disorders: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Citicoline is a chemical compound involved in the synthesis of cell membranes. It also has other, not yet explained functions. Research on the use of citicoline is conducted in neurology, ophthalmology, and psychiatry. Citicoline is widely available as a dietary supplement. It is often used to enhance cognitive functions. In our article, accessible databases were searched for articles regarding citicoline use in neurological diseases. This article has a systemic review form. After rejecting non-eligible reports, 47 remaining articles were reviewed. The review found that citicoline has been proven to be a useful compound in preventing dementia progression. It also enhances cognitive functions among healthy individuals and improves prognosis after stroke. In an animal model of nerve damage and neuropathy, citicoline stimulated regeneration and lessened pain. Among patients who underwent brain trauma, citicoline has an unclear clinical effect. Citicoline has a wide range of effects and could be an essential substance in the treatment of many neurological diseases. Its positive impact on learning and cognitive functions among the healthy population is also worth noting.

show abstract

Section: Resultsmentioning

confidence: 99%

Application of Citicoline in Neurological Disorders: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In some research, the minimum duration of 14 days 38,41,43,46,47 and a minimum dose that can provide a better clinical outcome is 1000 mg/day for phosphatidylcholine. 48,49 In this study, the mean phosphatidylcholine intake in the intervention group is still a deficit. The subjects receive the treatment by enteral tube in the acute phase (1-3 days after stroke onset) followed by oral administration.…”

Section: Discussionmentioning

confidence: 71%

The effect of additional protein, phosphatidylcholine, phosphatidylserine, and inulin on S100β levels of acute ischemic stroke patients at Dr. Kariadi Central Hospital, Semarang

Renamastika

Mahati

Kartasurya

et al. 2021

JGI

View full text Add to dashboard Cite

Background: The brain releases biochemical substrates, such as S100β protein, into circulation in response to ischemic conditions as a sign of damage in nerve cells and disruption of the blood-brain barrier’s integrity. Thrombolytic therapy has led to the development of many neuroprotective therapies such as protein, phosphatidylcholine, phosphatidylserine, and inulin, which can be added to food products. Protein, phospholipids, and inulin, have a neuroprotective impact on nerve cells in the brain and blood-brain barrier.Objective: To prove the effect of protein, phosphatidylcholine, phosphatidylserine, and inulin on S100β levels and clinical outcomes in patients with acute ischemic stroke.Materials and Methods: This study was done in a single-blind RCT. Eighteen ischemic stroke patients were randomly divided into nine subjects for the intervention group and nine subjects for the control group. The Control group received 250 ml conventional formula milk (11.8 g protein) 3 times/day. The intervention group received 250 mL commercial milk 3 rimes/day which contained 15 g protein with 128 mg phosphatidylcholine, 32 mg phosphatidylserine, and 3 g inulin. All of the groups were given hospital-standard therapy for ischemic stroke. S100β levels were measured at pre and post-intervention.Results: Pre and post S100β levels in intervention and the control group did not show any statistically difference (p = 0.777 and p = 0.096), but there was a trend of decreasing levels of S100β in the intervention group (-24.6 + 252.0 pg/mL) versus control group (135.8 + 216.2 pg/mL).Conclusions: The addition of protein, phosphatidylcholine, phosphatidylserine, and inulin did not have a significant effect on S100β levels.

show abstract

“…Citicoline efficacy was significantly (p <0.05) higher in patients aged less than 70 years and if citicoline was given in the first hours of the stroke (Martynov et al 2013).…”

Section: Discussionmentioning

confidence: 94%

“…Another study on the effectiveness citicoline use in patients with acute phase ischemic stroke was reported Martynov et al (2013) by observing the dynamics of neurological symptoms were assessed using Scandinavian Stroke Scale (SSS), Barthel Index and Modified Rankin Scale and functional in 89 severe ischemic stroke patients in acute phase. A 1000 mg citicoline was given by intravenous infusion during the first 7 days followed with oral administration in a dose of 1000 mg two weeks later.…”

Section: Discussionmentioning

confidence: 99%

Injected Citicoline Improves Impairment and Disability During Acute Phase Treatment in Ischemic Stroke Patients

Wahyudi¹,

Hasmono²,

Fitrina³

et al. 2016

FMI

View full text Add to dashboard Cite

ABSTRAKStrategi pengobatan stroke iskemik adalah mengurangi ukuran kerusakan dan penyelamatan sel-sel syaraf dari kematian pada masa awal kejadian iskemik. Recombinant-Tissue Plasminogen Activator (r-TPA) ABSTRACT Treatment strategy of ischemic stroke is to reduce the extent of the damage and rescue neurons from death in the early days of ischemic events. Recombinant Tissue-Plasminogen Activator (r-TPA) is the only recommended therapy, but their use is very limited. Citicoline is a neuroprotectant with a therapeutic effect on several stages of the ischemic cascade. However, its use is still being debated. The purpose of this study was to analyze the use of supplementation citicoline injection in patients with acute ischemic stroke in relations to differences in changes in the level of interference (impairment), rate limitation (disability) and the level of obstruction (handicap) between the group receiving supplementation of citicoline injection 2x500 mg iv and the group without supplementation during acute phase treatment. This study was a prospective cohort study using experimental design in patients with acute ischemic stroke who met the inclusion and exclusion criteria with or without supplementation citicoline between JanuaryApril 2015 in the National

show abstract

Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke

Cited by 7 publications

References 27 publications

Application of Citicoline in Neurological Disorders: A Systematic Review

Application of Citicoline in Neurological Disorders: A Systematic Review

The effect of additional protein, phosphatidylcholine, phosphatidylserine, and inulin on S100β levels of acute ischemic stroke patients at Dr. Kariadi Central Hospital, Semarang

Injected Citicoline Improves Impairment and Disability During Acute Phase Treatment in Ischemic Stroke Patients

Contact Info

Product

Resources

About